Helen Blackburn
Primary Care · Denton, NCNPI 1932215563
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 231 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,033 and has fallen 56.3% since, to $451 in 2025. Among primary care clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 231 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$521
- Novo Nordisk$470
- Lilly USA, LLC$459
- AbbVie$289
- Exact Sciences$255
- GSK$173
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,682100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $521 |
| Novo Nordisk | 32 | $470 |
| Lilly USA, LLC | 28 | $459 |
| AbbVie | 22 | $289 |
| Exact Sciences | 12 | $255 |
| GSK | 11 | $173 |
| Astellas Pharma US Inc | 11 | $169 |
| Merck | 9 | $152 |
| Boehringer Ingelheim | 9 | $142 |
| Kowa Pharmaceuticals America, Inc. | 9 | $134 |
| Novartis | 8 | $115 |
| Bayer | 6 | $100 |
| Pfizer | 4 | $73 |
| Biohaven Pharmaceuticals, Inc. | 5 | $70 |
| Amarin Pharma, Inc. | 4 | $63 |
| Lundbeck LLC | 4 | $59 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Shield Therapeutics Inc | 3 | $52 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Eisai Inc. | 2 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Medtronic | 1 | $25 |
| Abiomed | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $21 |
| OWP Pharmaceuticals, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
| Genentech USA, Inc. | 2 | $7 |
How this compares
$3,682 in reported general payments places this provider in the 90th percentile of 236 primary care providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $89,464 |
| RybelsusSemaglutide | 59 | $77,007 |
| EliquisApixaban | 78 | $70,110 |
| JardianceEmpagliflozin | 62 | $59,447 |
| OzempicSemaglutide | 44 | $53,248 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $30,776 |
| MounjaroTirzepatide | 17 | $25,668 |
| FarxigaDapagliflozin Propanediol | 20 | $20,908 |
| LinzessLinaclotide | 17 | $14,197 |
| XareltoRivaroxaban | 16 | $11,861 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $11,386 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $8,356 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $6,510 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $5,835 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 233 | $5,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $470 | $130,255103 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $173 | $99,302146 claims |
| PfizerEliquis | $73 | $70,11078 claims |
| Boehringer IngelheimJardiance | $142 | $59,44762 claims |
| AstraZenecaFarxiga, Symbicort | $521 | $32,29451 claims |
| Lilly USA, LLCMounjaro | $459 | $25,66817 claims |
| AbbVieLinzess, Synthroid | $289 | $15,33929 claims |
| MerckJanumet Xr | $152 | $5,83512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 236 primary care providers in North Carolina.
Other primary care in Denton
- Jessica AllynRaleigh$21K
- Jennifer RogersWinston Salem$17K
- Elizabeth WaltersChapel Hill$14K
- Ragan JohnsonChapel Hill$13K
- Kirkland DickeyPine Hall$11K
- Kimberly WeaverHickory$9K
- Amanda StoneWilmington$9K
- Elizabeth WalshGreensboro$7K
- Mark HollingsworthWilmington$7K
- Crystal GoinsFayetteville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.